Quarterly report pursuant to Section 13 or 15(d)

Restatement of Condensed Consolidated Balance Sheet and Related Statements of Operations and Cash Flows - Schedule of Restatement (Details)

v3.8.0.1
Restatement of Condensed Consolidated Balance Sheet and Related Statements of Operations and Cash Flows - Schedule of Restatement (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Total other income (expense), net $ 487 $ (1,980) $ 1,797 $ (5,447)  
Total net loss $ (2,069) (5,187) $ (4,284) (13,639)  
Deemed dividend related to beneficial conversion feature and accretion of a discount Series A preferred stock      
Net loss attributable to common stockholders $ (2,069) $ (5,187) $ (4,284) $ (13,639)  
Net loss per share attributable to common stockholders: Basic and diluted $ (0.68) $ (5.97) $ (1.47) $ (15.21)  
Weighted average common shares outstanding: Basic and diluted 3,022,073 1,920,745 2,918,240 1,309,286  
Common stock, $0.01 par value $ 30   $ 30   $ 22
Additional paid-in capital 225,733   225,733   222,513
Accumulated deficit (215,323)   (215,323)   (211,300)
Total stockholders' equity 10,440   10,440   11,235
Derivative liabilities, current portion 1,031   1,031   $ 3,137
Scenario, Previously Reported [Member]          
Total other income (expense), net (259)   (989)    
Total net loss $ (2,815)   $ (7,070)    
Deemed dividend related to beneficial conversion feature and accretion of a discount Series A preferred stock      
Net loss attributable to common stockholders $ (2,815)   $ (7,070)    
Net loss per share attributable to common stockholders: Basic and diluted $ (0.93)   $ (2.42)    
Weighted average common shares outstanding: Basic and diluted 3,022,073   2,918,240    
Common stock, $0.01 par value $ 30   $ 30    
Additional paid-in capital 231,647   231,647    
Accumulated deficit (220,206)   (220,206)    
Total stockholders' equity 11,471   11,471    
Derivative liabilities, current portion